
A Randomized Controlled Trial Comparing Mupirocin and Polysporin Triple Ointments in Peritoneal Dialysis Patients: The MP3 Study

McQuillan RF, Chiu E, Nessim S, et al. Clin J Am Soc Nephrol 2012;7:297-303





RPN Education Day - April 25, 2013



Perit Dial Int 2005;25:107-3 Perit Dial Int 2011:31:614-3

MP3 Trial

Objective:

To assess if the application of Polysporin Triple (P3) ointment to the PD catheter exit site is superior to mupirocin ointment in the prevention of PD-related infections

Design:

• Multi-centre, randomized, double-blind, controlled

Population:

- Inclusion: age ≥18 yrs; "medically stable" Exclusion: ARF; current catheter-related infection or infection within past 3 months; PO, IV or IP antibiotics at randomization or within past 1 week; allergy to any component of P3 or mupirocin; LRD within 6 months of study completion date

MP3 Trial

Intervention:

- P3 ointment vs. mupirocin ointment applied to PD catheter exit site using cotton-tipped applicator with each dressing change
- No other exit-site applications outside protocol allowed


Follow-up:

• 18 months or until death or catheter removal

Outcomes:

- 1° Endpoint: time to first PD-related infection (exit-site infection, tunnel infection and/or PD peritonitis)
- 2° Endpoints: catheter removal for refractory infection, hospitalization due to PD-related infection, death due to PD-related infection, all-cause mortality, and transfer to HD


Characteristic	P3 (n=101)	Mupirocin (n=100)	
Age (yr)	59.36 <u>+</u> 15.04	61.02 <u>+</u> 13.66	
Sex (% male)	62	66	
Ethnicity (% Caucasian)	38	43	
Median time on PD (months)	20.3	17.1	
CAPD: Incident (%)	16	16	
Prevalent (%)	32	31	
APD: Incident (%)	14	17	
Prevalent (%)	39	36	
Diabetes (%)	46	42	
Immunosuppressants (%)	10	11	
Previous PD peritonitis (%)	25	36	
Previous HD (%)	28	34	
Baseline MRSA positive (%)	3.2	4.3	
Previous mupirocin use (%)	55	51	



Characteristics of First PD-related Infections

Type of Catheter- Related Infection	P3 (n=101)	Mupirocin (n=100)	P Value	
Peritonitis	23	28	0.48	
Gram-positive	13	15	0.71	
Gram-negative	2	6	0.16	
Fungal		0	0.31	
Culture negative	7	7	1.00	
Exit-site infection	16	8	0.10	
Gram-positive	7	5	0.56	
Gram-negative		2	0.56	
Fungal	6	0	0.01	
Culture negative	2	1	0.56	

75 patients with PD-related infections (P3 39 vs. mupirocin 36) (Peritonitis - 51; Exit-site infections - 24; Tunnel infections - none)



Infection Rates Over Full Duration of Study

Type of Catheter- Related Infection	P3		Mupirocin		D.V-I
	n	Rate	n	Rate	P Value
Peritonitis	40	0.37	48	0.40	0.39
Gram-positive	24	0.22	25	0.21	0.88
Gram-negative	4	0.04	13	0.11	0.03
Fungal	4	0.04	0	0.00	0.05
Culture negative	8	0.07	10	0.08	0.64
Exit-site infection	30	0.28	14	0.12	0.02
Gram-positive	9	0.08	6	0.05	0.43
Gram-negative	10	0.09	5	0.04	0.20
Fungal	8	0.07	1	0.01	0.02
Culture negative	3	0.03	2	0.02	0.65
PD-related Infections	70	0.65	62	0.52	0.48

Conclusion

- Application of P3 ointment to the PD catheter exit site was not shown to be superior to mupirocin ointment in the prevention of PD-related infections
- Lower incidence of gram-negative peritonitis with P3 ointment vs. mupirocin ointment but higher incidence of fungal peritonitis and fungal exit-site infections
- Higher incidence of rash with P3 ointment (n=14) vs. mupirocin ointment (n=6)

Study Critique


Strengths:

- Randomization, allocation concealment and blinding well done
- Assessed hard clinical endpoints, e.g. all-cause/PD-related death and all-cause/PD-related hospitalization
- Canadian study (2 sites in Ontario)

Limitations:

- Short follow-up period (18 months) but median time to first PD-related infection ~14 months
- Adverse events not systematically assessed
- High discontinuation rates in both groups (slightly higher in P3)
- Increased fungal infections with P3 \rightarrow hypothesis generating
- Helpful to include 3rd arm with gentamicin ointment

Clinical Application



site cannot be recommended to prevent PD-related infections!